While 3M shares have significantly underperformed the broader market and its industrial peers over the past year, Wall Street maintains a cautiously optimistic stance, betting on the diversified giant's long-term recovery and earnings resilience.
While Boise Cascade's five-year total shareholder return of 110% has significantly outperformed its modest earnings growth, the building materials firm's recent stock slump raises questions about its valuation and future trajectory in a volatile market.
Merck & Co. is set to report fourth-quarter 2025 results before the bell on Tuesday, with Wall Street anticipating steady growth. The pharmaceutical giant's shares have climbed 13% over the past year, outpacing the broader healthcare sector. All eyes will be on Keytruda's sales trajectory and management's guidance for the year ahead.
New federal data reveals a significant year-over-year jump in energy costs for November, with natural gas prices soaring and electricity rates climbing, squeezing household budgets amid fluctuating demand and generation patterns.
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Despite a sharp sell-off in its shares, HubSpot reports a surge in new contract signings and projects an expanding free cash flow margin, signaling underlying operational strength even as investors remain wary.
Piper Sandler raises its price target on Kura Sushi USA (KRUS) following an investor meeting, citing potential from recent changes to its digital loyalty platform. The company also appointed a new marketing-focused director as it eyes U.S. expansion.
Morgan Stanley has upgraded Johnson & Johnson to 'Overweight,' raising its price target to $262, citing confidence in the healthcare giant's robust pipeline of new pharmaceuticals and medical devices.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Gold and silver prices tumbled from recent highs following the Fed chair nomination, prompting analysts to debate whether the sell-off marks a healthy correction or a shift in the long-term hedge narrative.
TD Cowen reaffirms its Buy rating on Dynatrace (DT) while adjusting its price target, anticipating stronger-than-expected performance driven by its new AI-powered observability platform, Dynatrace Intelligence.
Shares of real estate investment trust Curbline Properties (CURB) have gained momentum, closing recently at $24.25. With reported revenue of $163.7 million and net income of $41 million, the stock appears undervalued by some metrics. However, a sky-high P/E ratio and sector headwinds prompt a closer look at whether the market is pricing in unrealistic growth.
Zions Bancorporation has authorized a new $75 million stock repurchase program, a move analysts see as a bet on its undervalued shares and a commitment to shareholder returns as regional banks navigate a cautious regulatory environment.
Barclays reaffirms its Overweight rating on Meta Platforms, raising its price target to $800, citing robust Q4 recovery and surging ad revenue. The upgrade follows CEO Mark Zuckerberg's announcement of a massive $115B-$135B AI infrastructure investment plan for 2026.
Iconic bootmaker Dr. Martens has seen its market value erode by over £80 million, with shares falling 87% over five years. The prolonged decline raises questions about the brand's strategy in a shifting retail landscape.
An AI-driven analysis suggests JPMorgan Chase stock could see a slight decline to around $295 by mid-April, as the banking giant contends with rising operational costs and regulatory uncertainty, despite strong fundamentals and shareholder returns.
U.S. stocks and precious metals fell sharply Monday as President Trump's surprise nomination of Kevin Warsh to lead the Federal Reserve injected fresh uncertainty into markets, reversing a recent dollar slump and cooling a historic gold rally.
Bitcoin's recent price action, while volatile, is aligning with a late-stage corrective pattern. Technical analysis suggests the bearish sequence is nearing exhaustion, potentially setting the stage for a significant rebound toward the $100,000 mark before the next major trend emerges.
After a recent pullback, shares of French construction materials giant Saint-Gobain are trading at a notable discount to analyst targets. While long-term performance remains robust, investors are weighing near-term risks against potential value.
A deep dive into valuation metrics suggests Martin Marietta Materials (MLM) shares may be pricing in an overly optimistic outlook for construction growth, with key models indicating potential overvaluation.
